Neurology & CNS patent intelligence

US 9066943

Use of botulinum toxin therapy for treatment of urological neurological conditions

The Regents of the University of Colorado · Granted Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9050299

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California · Granted Tue Jun 09 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 9034923

Methods for the treatment of senile dementia of the alzheimer's type

Phenomenome Discoveries Inc. · Granted Tue May 19 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8951968

Methods of treating depression and other related diseases

Northwestern University · Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8951794

Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

The Regents of the University of California · Granted Tue Feb 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8945858

Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory

The Regents of the University of California · Granted Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8937060

1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders

Addex Pharma, S.A. · Granted Tue Jan 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8900574

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Dec 02 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8895579

Heterotricyclic AMPA receptor antagonists for treatment of epilepsy, pain, and other neurological disorders and diseases

Northwestern University · Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8895018

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

The United States of America as represented by the Department of Veteran Affairs · Granted Tue Nov 25 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 20 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8889627

Treatment of multiple sclerosis with combination of laquinimod and fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8877797

Methods for treating Parkinson's disease using pro-neurogenic compounds

The Board of Regents of the University of Texas System · Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8859585

Scopolamine for the treatment of depression and anxiety

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8852626

Controlled-release CNS modulating compositions and methods for the treatment of otic disorders

The Regents of the University of California · Granted Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8759314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8759302

Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 24 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 19 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8748472

Stabilized formulations of CNS compounds

Supernus Pharmaceuticals, Inc. · Granted Tue Jun 10 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8741880

Antiglucocorticoid therapy for the prevention of neurological damage in premature infants

Corcept Therapeutics Incorporated · Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8697060

Treatment method for relapsing-remitting multiple sclerosis

REGENEX LLC · Granted Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8685404

Recombinant T-cell receptor ligand for the treatment of cognitive and neuropsychiatric impairment induced by substance addiction

United States Government as represented by the Department of Veterans Affairs · Granted Tue Apr 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8663987

Mesenchymal stem cells for the treatment of CNS diseases

BRAINSTORM CELL THERAPEUTICS LTD. · Granted Tue Mar 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 27 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8636997

Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jan 28 2014 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8617549

Bispecific nanobodies as a therapeutic for alzheimer's disease

ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Dec 31 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8524655

Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders

Northwestern University · Granted Tue Sep 03 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8492340

Methods of treating depression and other related diseases

Northwestern University · Granted Tue Jul 23 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8454965

Method for the treatment of multiple sclerosis

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jun 04 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8420852

Phospholipase A2 inhibitors and their use in treating neurological injury and disease

The Regents of the University of California · Granted Tue Apr 16 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8415314

Methods for treating multiple sclerosis using antisense oligonucleotides

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 09 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8409548

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California · Granted Tue Apr 02 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8394583

VH4 codon signature for multiple sclerosis

The Board of Regents of the University of Texas System · Granted Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8394380

Compositions and methods for alzheimer's disease

Primex Clinical Laboratories, Inc. · Granted Tue Mar 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8389478

Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

The Regents of the University of California · Granted Tue Mar 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 28 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8372826

Estriol therapy for multiple sclerosis and other autoimmune diseases

The Regents of the University of California · Granted Tue Feb 12 2013 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 07 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8309355

Methods of treating Parkinson's disease using viral vectors

The Regents of the University of California · Granted Tue Nov 13 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8298525

Method of treating multiple sclerosis with interferon-beta and an IL-2R antagonist

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8293800

Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Oct 23 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 18 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8232373

Immunogenic peptide composition for the prevention and treatment of alzheimer's disease

United Biomedical, Inc. · Granted Tue Jul 31 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8153604

CNS-tumor treatment method and composition

The Regents of the University of California · Granted Tue Apr 10 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 05 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8129334

Methods and compositions for treating neurodegenerative disorders and Alzheimer'S disease and improving normal memory

The Regents of the University of California · Granted Tue Mar 06 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 01 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 8101380

Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs

The United States of America, as represented by the Secretary, Health and Human Services · Granted Tue Jan 24 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7968511

Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7922999

Administration of growth factors for the treatment of CNS disorders

The Regents of the University of California · Granted Tue Apr 12 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7879548

Detection of biomarkers for neuropsychiatric disorders

The Regents of the University of California · Granted Tue Feb 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 27 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7846892

Compositions and methods for Alzheimer's disease

Primex Clinical Laboratories, Inc. · Granted Tue Dec 07 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7829279

Compositions and methods for diagnosis and treatment of epilepsy

The Regents of the University of California · Granted Tue Nov 09 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7727957

Treatment and delay of outset of Parkinson's disease

The Regents of the University of California · Granted Tue Jun 01 2010 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 27 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7622461

Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders

ACADIA Pharmaceuticals Inc. · Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

US 7619005

Methods for treating cognitive impairment in humans with Multiple Sclerosis

Cognition Pharmaceuticals, LLC · Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)